Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goetz, C. G.
Right arrow Articles by Carroll, V. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goetz, C. G.
Right arrow Articles by Carroll, V. S.
NEUROLOGY 1987;37:875
© 1987 American Academy of Neurology

Parkinson's disease and motor fluctuations

Long-acting carbidopa/levodopa (CR-4-Sinemet) C. G. Goetz, MD, C. M. Tanner, MD, H. L. Klawans, MD, K. M. Shannon, MD and V. S. Carroll, MS

Department of Neurological Sciences, Rush-Presbyterian St. Luke's Medical Center, Chicago, IL.

long-acting levodopa/carbidopa combination (CR-CSinemet) was compared with traditional levodopa/carbidopa (Sinemet) open label in 20 patients with Parkinson's disease and "wearing-off" phenomena. After 4 to 6 weeks of therapy with CR-4-Sinemet, the number of daily doses of medication dropped significantly compared with traditional Sinemet, disability improved, and "on" time increased. In nine patients receiving CR-4-Sinemet for 3 months, the number of daily doses and the on time without chorea remained significantly improved. CR-4-Sinemet peaked in plasma after 2 hours, and moderately high levels remained at 4 hours after the dose. Side effects were similar between traditional Sinemet and CR-4 Sinemet.

Address correspondence and reprint requests to Dr. Goetz, Department of Neurological Sciences, Rush-Presbyterian St. Luke's Medical Center, 1753 West Congress Parkway, Chicago, IL 60612.

Received June 12, 1986. Accepted for publication in find form August 27, 1986.




This article has been cited by other articles:


Home page
 NeurologyHome page
R. B. Dewey Jr.
Management of motor complications in Parkinson's disease
Neurology, March 23, 2004; 62(6_suppl_4): S3 - S7.
[Abstract] [Full Text]

Home page
 Arch NeurolHome page
J. T. Hutton, J. L. Morris, G. C. Roman, S. C. Imke, and J. W. Elias
Treatment of Chronic Parkinson's Disease With Controlled-Release Carbidopa/Levodopa
Arch Neurol, August 1, 1988; 45(8): 861 - 864.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
R. Kurlan
Dietary Therapy for Motor Fluctuations in Parkinson's Disease
Arch Neurol, November 1, 1987; 44(11): 1119 - 1121.
[Abstract] [PDF]